More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

S&P DJI Announces March 2022 Quarterly Rebalance

Mar 4, 2022 at 6:22 AM EST · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Mar 4, 2022 at 6:22 AM EST · 10 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2022-quarterly-rebalance-62

Paradigm Biopharmaceuticals Ltd. on 6ix

Story so far

  • S&P DJI Announces June 2020 Quarterly RebalanceJun 12, 2020
  • S&P DJI Announces March 2019 Quarterly RebalanceMar 8, 2019

Earlier from Paradigm Biopharmaceuticals

  • Paradigm 1HY22 Key Activity HighlightsFeb 23, 2022
  • Paradigm treats first subjects in phase 3 trial of ZilosulJan 12, 2022
  • PAR reports postive topline results in heart failure modelDec 16, 2021
  • Preliminary Results from Phase 2 MPS I StudyNov 22, 2021
  • Paradigm CEO Paul Rennie to transition to Non-Exec ChairmanNov 21, 2021

Later from Paradigm Biopharmaceuticals

  • Clarification of recent analyst report on Patent ProtectionMar 9, 2022
  • FDA Grants Paradigm Fast Track Designation For OAApr 12, 2022
  • Paradigm Doses First US Subjects under Phase 3 trialApr 28, 2022
  • Paradigm Appoints Experienced US-Based CEOMay 29, 2022
  • Paradigm Receives $8.2m R&D Tax Incentive RefundJun 6, 2022
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer